|Rank||House||Value (USD m)||Number of Deals|
Source: Mergermarket, Novus Capital analysis
Note: Announced deals in the pharmaceutical industry in Russia in 2012-2020
Novus Capital provides a full range of advisory services in M&A transactions: sale and acquisitions of companies/assets, devision of the companies and mergers. Our team engages industry experts and market specialists that helps us evaluating the rationale and deal probability.
Due to our deep industry knowledge and understanding the specifics of the regulatory environment on the Russian pharmaceutical market our team has built long terms relationship with the top management and owners of Russian and multinational companies as well as with other market stakeholders (media, regulatory and public bodies). The combination of all of the above factors help us to be engaged in key M&A transactions on the Russian market.
Novus Capital advises in capital raising transactions for companies willing to finance its development. We help determining the necessary size of the investment capital, optimal split between equity and debt financing, deal structure as well as the list of the most probable investors/lenders.
Novus Capital advises Russian and international companies and funds on 1) capital raising 2) selling secondary shares 3) divestiture
Novus Capital acted as the financial advisor to Glenmark Pharmaceuticals and organized a highly competitive closed auction process. In line with the strategy to launch Ryaltris, the global anti-allergy brand, in the markets of Russia and other CIS countries, Glenmark Pharmaceuticals Ltd. decided to divest the Momat Rino brand and its extensions in Russia, Ukraine, Kazakhstan and Uzbekistan
Novus Capital acted as the financial advisor to ASNA Group in the process of raising equity financing from JSC Gazprombank. ASNA Group is the №1 player on the Russian retail pharmaceutical market that unites approximately 11.5 thousand independent pharmacies
Novus Capital acted as the financial advisor to Teva Pharmaceuticals in the process of attracting buyers and facilitating negotiations with them. Teva Pharmaceuticals made a decision to sell its pharmaceutical plant in Russia (city of Yaroslavl) as a part of the general program for the restructuring of its production infrastructure
Novus Capital acted as a financial advisor in the transaction on the side of Salvim LLC. As a result of negotiations in November 2019, Salvim LLC and Gedeon Richter Plc signed an agreement to sell Oralsept product line.
Novus Capital acted as the financial adviser for Unipharm, a leading regional OTC company, in the acquisition of melatonin based product on the Russian market from Profit Pharm
Novus Capital acted as a financial advisor to the owners of the Russian company Active Component in a process of selling of a stake to Elbrus Capital (Private Equity Fund). Active component is the leading manufacturer of active pharmaceutical ingredients in Russia.
Novus Capital acted as the financial adviser for the owners of Russian company ALSI Pharma in the sale to the strategic investor Xantis Pharma. ALSI Pharma is a leading company in Russia manufacturing generics. The company specilizes in production of cardiovascular products and drugs for cenral nervous system.
Novus Capital acted as financial advisers for the owners of Dolphin product line, a leading over-the-counter product (medical device) for the treatment of sinusitis (infections of the paranasal sinus) in Russia, in business sale to American company Alvogen
Novus Capital partners acted as the financial advisors to the owners of Aqualor brand, the leading over-the-counter product for rinsing the nasal cavity on the Russian market, in selling the product to the strategic investor
Novus Capital partners acted as the financial advisors to Akvion, one of the leading manufacturers of food supplements and pharmaceutical products on the Russian market, in selling the portfolio of five products to the strategic investor
RADLogics develops AI-Powered solutions that support image analysis to improve radiologists’ productivity while enhancing patient outcomes.
Novus Capital acted as a financial advisor to the founders in raising of Round B financing
LOLOCLO is a Russian startup showing rapid growth in the children’s clothes segment. The company manufactures and sells all basic wardrobe for children from 0 to 12 years old using the DTC promotion model.
Novus Capital acted as a financial advisor to the founders in raising Round A financing
Polyn Technology is a high-tech startup that has developed a mathematical algorithm that allows converting almost any trained neural network into a package of technical documentation and then “print” such a network “on silicon” in the form of a neuromorphic analog chip.
Novus Capital acted as a financial advisor to the founders in raising seed round of financing
Novus Capital acted as a financial adviser for the shareholders of Genotek, one of the leading DNA testing companies in Russia in raising capital and a private placement
Novus Capital acted as the financial advisor to a leading Russian pharmaceutical communication agency Aaron Lloyd in the creation of the joint venture in Russia with the leading global communications agency Dentsu Aegis Network
Novus Capital partners acted as the financial advisors to Pharmexpert Group, the leading analytical company for the pharmaceutical industry in Russia, in negotiations, structuring and closing the sale of its business to IMS Health - a leading provider of information, services and technology for the healthcare industry globally
Sergey focuses on mergers and acquisitions and capital raising advisory in Russia. Sergey has been managing numerous M&A engagements in various industries, including pharmaceuticals, FMCG, banking, packaging, metals and mining, oil & gas and others.
Before BIC Securities Sergey worked at KMPG Corporate Finance (Moscow office) for more than 3 years, where he was involved in M&A and fund raising projects.
Sergey graduated from Finance University under the Government of the Russian Federation.
Aleksandr focuses on mergers and acquisitions and capital raising advisory. Aleksandr has been advising and managing M&A transactions in pharmaceuticals, media, industrial packaging, food and beverages.
Before establishing Novus Capital, Aleksandr worked at BIC Securities as a Managing Director and Head of Pharmaceutical and Healthcare practice for more than 5 years. Before BIC Securities, in 2004-2009 Aleksandr was working at Partner position in Prudentia, one of the leading Baltic investment banking firms. During his work in Prudentia Aleksandr specialized in origination and execution of numerous corporate finance advisory engagements and M&A projects. Prior to Prudentia Aleksandr worked in the Corporate Advisory Services Department in Ernst & Young Baltic, as an Economist in the Analytical Department of the Central Bank of Latvia, and also as an Analyst at the Riga Stock Exchange.
Aleksandr holds a B.Sc. degree in Economics from the Stockholm School of Economics in Riga. He has also taken courses in Economics and Business from the Harvard Business School and completed the first level of CFA examination.
Denis specializes in mergers and acquisitions in the field of health, pharmaceuticals and IT.
Prior to joining Novus Capital, Denis worked for Rosnano for 3 years as a chief investment analyst, where he was responsible for structuring transactions, financial modeling and supporting 4 Rosnano portfolio companies with 20 to 100% participation shares and total investments of more than 30 billion rubles. Denis participated in numerous analyses of project applications.
Before joining Rosnano, Denis worked at KPMG in the transaction support department (financial due diligence), where he was responsible for financial expertise of projects, analysis of companies and the industry, identifying financial and business risks in 7 projects mainly in the financial sector.
Before joining KPMG, he worked for 5 years as an auditor in the audit department of E & Y and PwC in the financial sector, where he conducted an audit of financial statements according to the standards of RAS, IFRS and GAAP of more than 20 organizations.
Denis has a bachelor's degree in finance - Belarusian State Economic University. In addition, he successfully obtained an ACCA diploma.
Boris focuses on mergers and acquisitions (M&A) and fundraising in Russia. His experience includes projects in the field of telecommunications, technologies, oil and gas, industrial and agricultural sectors
Prior to joining Novus Capital Boris worked at ALTHAUS Group and EY (Ernst & Young), Business Valuation department as a Consultant. Boris was involved in business valuation projects for transaction purposes and fundraising
Boris holds B.Sc. and M.Sc. degrees from the Financial University under the Government of the Russian Federation, and M.Sc. of le CNAM, Paris
Christina focuses on mergers and acquisitions and capital raising advisory in Russia
Before joining Novus Capital Christina worked at the private corporate boutique as a financial analyst and specialised in financial modelling and corporate finance. Christina was involved in several projects related to capital raising
Christina has BSc in Economics from NRU Higher School of Economics and MSc in Financial Economics from ICEF, NRU Higher School of Economics
Niсkolai Demidov has joined Novus Capital as a Partner for the Healthcare and Digital practice in March 2021.
Niсkolai Demidov is a recognized expert in the pharmaceutical market. In November 2012, following the completion of the acquisition of the main assets of the Pharmexpert Group of companies by IMS Health, Niсkolai was appointed CEO of IMS Health Russia and the CIS. In 2016, Quintiles Transnational Holdings, a contract services company in the field of clinical research, and IMS Health Holdings, an information and analytical company, reached an agreement to merge. The combined company was renamed IQVIA, and Demidov became the General manager of its division in Russia and was responsible for data, technologies and consulting business in Russia, Ukraine and CIS. In March 2021, Niсkolai decided to continue his career in an advisory role for the pharmaceutical and healthcare companies on mergers, acquisitions and capital raisings.
Demidov graduated from the Russian Academy of Economics named after Plekhanov with a degree in Finance and Credit in 1998. In 2010, he received an MBA from AIBEC. In 2002, Niсkolai Demidov was appointed to the position of the Head of the Research Department of the company "Pharmexpert", in 2003 – to the position of the Executive Director, and in 2006 became the General Director of "Pharmexpert". Nickolai is a member of the Coordination council of Russian Pharmaceutical Marketing Association.
We believe that one of Novus Capital's success factors is our result orient team
We would be happy to invite to our team goal oriented people with good education and relevant experience, that are willing to reach new professional heights
If you are interested to join Novus Capital please send your CV to firstname.lastname@example.org
According to the results of the year 2020, the Novus Capital team placed second in the rating of Russian M&A consultants according to Preqveca (a portal dedicated to the Private Equity and venture financing industry in Russia).
© All rights reserved, 2015-2021